TheStreet upgraded shares of Zimmer Biomet (NYSE:ZBH) from a c+ rating to a b rating in a research report report published on Tuesday morning, TheStreetRatingsTable reports.

Other research analysts have also issued reports about the company. Needham & Company LLC reaffirmed a buy rating and issued a $170.00 target price on shares of Zimmer Biomet in a research report on Tuesday. Raymond James increased their target price on Zimmer Biomet from $150.00 to $160.00 and gave the stock an outperform rating in a research report on Wednesday. Oppenheimer increased their target price on Zimmer Biomet from $135.00 to $150.00 and gave the stock an outperform rating in a research report on Monday, July 29th. Zacks Investment Research raised Zimmer Biomet from a sell rating to a hold rating and set a $149.00 target price on the stock in a research report on Sunday, November 3rd. Finally, Jefferies Financial Group increased their target price on Zimmer Biomet from $150.00 to $167.00 and gave the stock a buy rating in a research report on Monday, July 29th. They noted that the move was a valuation call. One analyst has rated the stock with a sell rating, six have assigned a hold rating and nineteen have assigned a buy rating to the company’s stock. The company has a consensus rating of Buy and an average price target of $147.95.

Shares of ZBH opened at $144.00 on Tuesday. The company has a current ratio of 1.19, a quick ratio of 0.56 and a debt-to-equity ratio of 0.58. The firm has a market capitalization of $28.81 billion, a P/E ratio of 18.85, a price-to-earnings-growth ratio of 2.66 and a beta of 1.14. The stock’s fifty day simple moving average is $137.06 and its 200 day simple moving average is $128.64. Zimmer Biomet has a twelve month low of $96.99 and a twelve month high of $144.96.

Zimmer Biomet (NYSE:ZBH) last issued its earnings results on Tuesday, November 5th. The medical equipment provider reported $1.77 earnings per share for the quarter, topping the consensus estimate of $1.75 by $0.02. The business had revenue of $1.89 billion for the quarter, compared to analyst estimates of $1.87 billion. Zimmer Biomet had a positive return on equity of 13.89% and a negative net margin of 1.14%. The business’s quarterly revenue was up 3.0% on a year-over-year basis. During the same period last year, the company posted $1.63 EPS. Sell-side analysts predict that Zimmer Biomet will post 7.83 earnings per share for the current year.

The business also recently declared a quarterly dividend, which was paid on Thursday, October 31st. Investors of record on Monday, September 30th were issued a $0.24 dividend. The ex-dividend date was Friday, September 27th. This represents a $0.96 annualized dividend and a yield of 0.67%. Zimmer Biomet’s dividend payout ratio is currently 12.57%.

In other news, VP Chad F. Phipps sold 7,000 shares of the firm’s stock in a transaction dated Thursday, August 29th. The stock was sold at an average price of $138.28, for a total transaction of $967,960.00. Following the completion of the sale, the vice president now directly owns 37,722 shares in the company, valued at $5,216,198.16. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Didier Deltort sold 360 shares of the firm’s stock in a transaction dated Friday, September 6th. The shares were sold at an average price of $139.25, for a total value of $50,130.00. Following the sale, the insider now owns 1,194 shares of the company’s stock, valued at $166,264.50. The disclosure for this sale can be found here. Over the last quarter, insiders sold 40,244 shares of company stock valued at $5,621,885. 0.72% of the stock is owned by insiders.

Several institutional investors have recently made changes to their positions in ZBH. Personal Wealth Partners acquired a new stake in shares of Zimmer Biomet during the second quarter valued at about $26,000. TRUE Private Wealth Advisors acquired a new stake in shares of Zimmer Biomet during the second quarter valued at about $26,000. Allworth Financial LP grew its stake in shares of Zimmer Biomet by 65.0% during the third quarter. Allworth Financial LP now owns 203 shares of the medical equipment provider’s stock valued at $28,000 after acquiring an additional 80 shares in the last quarter. Coastal Investment Advisors Inc. grew its stake in shares of Zimmer Biomet by 271.0% during the second quarter. Coastal Investment Advisors Inc. now owns 256 shares of the medical equipment provider’s stock valued at $30,000 after acquiring an additional 187 shares in the last quarter. Finally, Private Ocean LLC grew its stake in shares of Zimmer Biomet by 34.8% during the second quarter. Private Ocean LLC now owns 310 shares of the medical equipment provider’s stock valued at $36,000 after acquiring an additional 80 shares in the last quarter. Institutional investors own 87.72% of the company’s stock.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, designs, manufactures, and markets musculoskeletal healthcare products and solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates through four segments: Spine, less Asia Pacific; Office Based Technologies; Craniomaxillofacial and Thoracic; and Dental.

Featured Story: What Does Beta Mean In Stock Selection?

Analyst Recommendations for Zimmer Biomet (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.